Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 452 participants.
Also called NCT06196320
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 452 participants
- Sponsor
- Registry
-
NCT06196320
-
- Other papers using this trial's data
- Tenecteplase versus standard care in patients with acute basilar artery occlusion: a multi-centre, prospective, randomised, open-label, blinded endpoint, phase 3, controlled trial
- Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): a multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06196320. Randomized; single masking; primary purpose treatment. Start 2024-01-24 (actual); primary completion 2025-09-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events-5
- Acronym
- TRACE-5
- Condition
- Ischemic Stroke, Acute
- Intervention (Drug)
- Tenecteplase
- Intervention (Drug)
- Best Practice (which may include intravenous Alteplase)
- Lead sponsor
- Beijing Tiantan Hospital
Record details
- Record id
cardio:ct-nct06196320- Content hash
9e8a3ac7b8c572b7a14d07edf906a122731955be25fea7fdeded0aaa9355f614